How India Exports Potassium to the World

In the United States, potassium chloride is approved by the FDA for the treatment and prevention of hypokalemia. The FDA's Orange Book lists multiple approved Abbreviated New Drug Applications (ANDAs) for potassium chloride extended-release tablets. For instance, Upsher-Smith Laboratories' KLOR-CON M20 (20 mEq) was approved on November 20, 1998, under ANDA number 074726. Additionally, Rubicon Research Private Limited received approval for their 15 mEq extended-release tablets on August 22, 2024, under ANDA number 215725. These approvals indicate a competitive market with multiple generic options available.

The regulatory pathway for potassium chloride involves submitting an ANDA, demonstrating bioequivalence to a reference listed drug (RLD). The FDA's Orange Book provides information on RLDs and reference standards, guiding generic manufacturers in their applications. Given the substantial export volume from India, with 877 active exporters and a 61.4% repeat buyer rate, maintaining compliance with FDA regulations is crucial for market access.

In the European Union and the United Kingdom, marketing authorization for medicinal products like potassium chloride is governed by the European Medicines Agency (EMA) and the Medicines and Healthcare products Regulatory Agency (MHRA), respectively. Manufacturers must obtain a Marketing Authorization (MA) by demonstrating the product's quality, safety, and efficacy. Compliance with Good Manufacturing Practice (GMP) standards, as outlined by the EMA, is mandatory. These standards ensure that products are consistently produced and controlled according to quality standards.

Potassium chloride is included in the World Health Organization's (WHO) Model List of Essential Medicines, underscoring its importance in healthcare systems worldwide. The WHO Prequalification Programme ensures that medicinal products meet global standards of quality, safety, and efficacy. Additionally, potassium chloride formulations are standardized in various pharmacopoeias, including the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP), providing consistent quality benchmarks for manufacturers and regulators.

In India, potassium chloride is classified under Schedule H of the Drugs and Cosmetics Act, indicating that it is a prescription drug requiring medical supervision. The National Pharmaceutical Pricing Authority (NPPA) regulates the pricing of essential medicines; however, as of March 2026, potassium chloride is not listed under the Drugs (Prices Control) Order (DPCO), implying no ceiling price is currently imposed. For exports, the Directorate General of Foreign Trade (DGFT) mandates a No Objection Certificate (NOC) to ensure compliance with national regulations and international standards.

The patent landscape for potassium chloride formulations is diverse, with various patents covering specific formulations and delivery mechanisms. The presence of multiple approved ANDAs, such as those by Upsher-Smith Laboratories and Rubicon Research Private Limited, indicates that many formulations are off-patent, allowing for generic competition. Manufacturers should conduct thorough patent searches to ensure freedom to operate and avoid infringement.

In August 2025, CuraTeQ Biologics, a subsidiary of Aurobindo Pharma Ltd., received marketing authorization from the UK's MHRA for Dazublys, a trastuzumab biosimilar, reflecting the company's expanding portfolio in the UK market.

In May 2025, the FDA issued draft guidance for industry on replacing color additives in approved or marketed drug products, providing recommendations for manufacturers considering such changes.

In December 2025, the FDA updated the Orange Book to clarify listings of reference listed drugs (RLDs) and reference standards, aiding generic manufacturers in identifying appropriate RLDs for their ANDA submissions.

In January 2026, the FDA published additions and deletions to the Prescription and OTC Drug Product Lists, reflecting ongoing updates to approved drug products.

In April 2025, the EMA's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for Dazublys, recommending its marketing authorization in the European Union.

These developments highlight the dynamic nature of the pharmaceutical regulatory landscape, emphasizing the importance for exporters to stay informed and compliant with evolving regulations.

India's pharmaceutical industry, renowned for its generic drug production, heavily relies on Active Pharmaceutical Ingredients (APIs) and Key Starting Materials (KSMs) imported from China. Approximately 70% of India's API requirements are sourced from China, underscoring a significant dependency on Chinese suppliers. This reliance exposes the supply chain to vulnerabilities, as any disruption in Chinese production or export policies can directly impact India's pharmaceutical manufacturing capabilities.

Recent geopolitical tensions and environmental regulations have led to the shutdown of several Chinese chemical manufacturing units, causing supply chain disruptions and price volatility in API markets. For instance, in 2024, the closure of Chinese factories due to environmental concerns resulted in increased prices for APIs and KSMs, affecting global pharmaceutical supply chains. Such events highlight the risks associated with overdependence on a single country for critical raw materials.

The export market for potassium-based pharmaceuticals from India is notably concentrated, with the top five exporters—led by AUROBINDO PHARMA LTD holding a 14.0% share—collectively accounting for 48.4% of total exports. This concentration poses a single-source risk, where disruptions affecting these key players could significantly impact the supply chain.

To mitigate such risks, the Indian government has implemented the Production Linked Incentive (PLI) scheme aimed at boosting domestic API and KSM production. In October 2024, two greenfield plants were inaugurated under this scheme to manufacture critical molecules like Penicillin G and 6-APA, essential for various antibiotics. These initiatives aim to reduce import dependence and enhance supply chain resilience.

Geopolitical tensions, particularly in the Middle East, have led to significant disruptions in global shipping routes. The closure of the Strait of Hormuz in March 2026, following military conflicts, has severely impacted the transportation of goods, including pharmaceuticals. Approximately 20% of global oil and LNG trade passes through this strait, and its closure has caused widespread logistical challenges and increased shipping costs. Such disruptions can delay shipments and escalate costs for Indian pharmaceutical exports, affecting global supply chains.

Additionally, the U.S. Food and Drug Administration (FDA) has been actively monitoring and addressing supply chain vulnerabilities to prevent drug shortages. In April 2024, the U.S. Department of Health and Human Services released a white paper outlining steps to prevent and mitigate drug shortages, emphasizing the need for a resilient pharmaceutical supply chain.

• Diversify API and KSM Sourcing: Reduce dependency on a single country by developing alternative sources for critical raw materials, including domestic production and partnerships with other countries.

• Enhance Domestic Manufacturing: Invest in local API and KSM manufacturing facilities through incentives and support programs like the PLI scheme to strengthen supply chain resilience.

• Strengthen Supplier Relationships: Foster long-term partnerships with multiple suppliers to mitigate risks associated with supplier concentration and ensure a stable supply chain.

• Monitor Geopolitical Developments: Establish a dedicated team to track geopolitical events and assess their potential impact on supply chains, enabling proactive risk management.

• Implement Advanced Logistics Planning: Develop contingency plans for shipping disruptions, including alternative routes and transportation methods, to ensure timely delivery of products.

RISK_LEVEL: MEDIUM